Alexander E. Barkas
Fondateur chez Prospect Venture Partners
Profil
Alexander E.
Barkas is the founder of Prospect Venture Partners, Biobridge Associates.
He was the Chairman at Tercica, Inc. from 2002 to 2008.
He served as the Lead Independent Director at Geron Corp.
in 2011.
From 1993 to 2005, he was a Director at Connetics Corp.
He also held director positions at Archemix Corp., CYTYC Surgical Products, Azelon Pharmaceuticals, Inc., Amicus Therapeutics, Inc., SurgRx, Inc., Verus Pharmaceuticals, Inc., Complete Genomics, Inc., Transave, Inc., Neomend, Inc., Advanced Biosearch Associates, and Topica Pharmaceuticals, Inc. Additionally, he worked as a Partner at Kleiner Perkins Caufield & Byers LLC from 1991 to 1997.
He also served as a Trustee at Brandeis University.
Barkas completed his undergraduate degree at Brandeis University and obtained a doctorate from New York University.
Postes actifs de Alexander E. Barkas
| Sociétés | Poste | Début |
|---|---|---|
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Fondateur | - |
Anciens postes connus de Alexander E. Barkas
| Sociétés | Poste | Fin |
|---|---|---|
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Directeur/Membre du Conseil | 01/11/2011 |
Verus Pharmaceuticals, Inc.
 Verus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/11/2011 |
| GERON CORPORATION | Président | 10/02/2011 |
Topica Pharmaceuticals, Inc.
 Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Directeur/Membre du Conseil | 01/11/2011 |
SurgRx, Inc.
 SurgRx, Inc. Medical SpecialtiesHealth Technology SurgRx, Inc. develops tissue sealing and cutting technology. The company's products include EnSeal, TRIO, PowerTip, RF-60, and universal RF Generator. It also develops vessel fusion system used in electrosurgical devices. The company was founded in 2001 and is headquartered in Redwood City, CA. | Directeur/Membre du Conseil | 01/11/2011 |
Formation de Alexander E. Barkas
| Brandeis University | Undergraduate Degree |
| New York University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
CYTYC Surgical Products
 CYTYC Surgical Products Pharmaceuticals: MajorHealth Technology CYTYC Surgical Products was founded to design, develop, manufacture and market innovative therapeutic devices that improve the quality of women's healthcare in a cost- effective manner. Its initial product, the Novasure Endometrial Ablation System, is used to treat women who suffer from excessive menstrual bleeding. | Health Technology |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
SurgRx, Inc.
SurgRx, Inc. Medical SpecialtiesHealth Technology SurgRx, Inc. develops tissue sealing and cutting technology. The company's products include EnSeal, TRIO, PowerTip, RF-60, and universal RF Generator. It also develops vessel fusion system used in electrosurgical devices. The company was founded in 2001 and is headquartered in Redwood City, CA. | Health Technology |
Verus Pharmaceuticals, Inc.
Verus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA. | Health Technology |
Complete Genomics, Inc.
 Complete Genomics, Inc. BiotechnologyHealth Technology Complete Genomics, Inc. develops and markets DNA sequencing technology. It provides complete genomics analysis platform, which combines its proprietary human genome sequencing technology with the company's advanced informatics and data management software. The firm offers innovative, end-to-end, outsourced service model to the customers with data. The company was founded by Clifford A. Reid, Radoje T. Drmanac, David Smith and Robert John Curson in 2006 and is headquartered in San Jose, CA. | Health Technology |
Kleiner Perkins Caufield & Byers LLC
 Kleiner Perkins Caufield & Byers LLC Investment ManagersFinance Kleiner Perkins Caufield & Byers LLC (Kleiner Perkins Caufield & Byers) is a venture capital firm founded in 1972 by Eugene Kleiner, Thomas Perkins, Brook Byers and Frank J. Caufield. The firm is headquartered in California, US. | Finance |
Prospect Venture Partners
Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Finance |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Neomend, Inc.
 Neomend, Inc. BiotechnologyHealth Technology Neomend, Inc. develops surgical wound healing products. It offers adhesion prevention products for hospitals and medical facilities. The company was founded in 1999 and is headquartered in Irvine, CA. | Health Technology |
| Biobridge Associates | |
| Advanced Biosearch Associates | |
Topica Pharmaceuticals, Inc.
Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Health Technology |